New immunotherapy combo aims to wipe out hidden colorectal cancer cells
NCT ID NCT07551596
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer who have completed standard treatment. The study enrolls 20 adults whose blood still shows signs of cancer. The goal is to see if the combination can eliminate these remaining cells and lower the chance of the cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- botensilimab and balstilimab (immunotherapy drugs)
- What this could lead to
- If successful, this could show that combining these two immunotherapy drugs can eliminate remaining cancer cells in the blood, potentially reducing the risk of cancer returning.
- What could go wrong
- This is a small, early-phase trial with only 20 participants. The drugs may cause immune-related side effects, and it is not yet known if clearing ctDNA will actually prevent cancer recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new blood test spot colorectal cancer return earlier?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Breath of life: new test could sniff out gut cancers before they spread
- Gut instinct: listening to bowel sounds may reveal hidden clues about surgical recovery
- Experimental drug combo targets Hard-to-Treat GI cancers